Zobrazeno 1 - 10
of 138
pro vyhledávání: '"Arthur R Thompson"'
Autor:
Jasper C Lin, Ruth A Ettinger, Jason T Schuman, Ai-Hong Zhang, Muhammad Wamiq-Adhami, Phuong-Cac T Nguyen, Shelley M Nakaya-Fletcher, Komal Puranik, Arthur R Thompson, Kathleen P Pratt
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e0116577 (2015)
The development of neutralizing anti-factor VIII (FVIII) antibodies complicates the treatment of many hemophilia A patients. The C-terminal C2 domain is a particularly antigenic FVIII region. A crystal structure of recombinant FVIII-C2 bound to an Fa
Externí odkaz:
https://doaj.org/article/9f01ce1acfea4daca262cfb00998c208
Autor:
Ruth A. Ettinger, Joseph A. Liberman, Devi Gunasekera, Komal Puranik, Eddie A. James, Arthur R. Thompson, Kathleen P. Pratt
Publikováno v:
Blood Advances, Vol 2, Iss 4, Pp 309-322 (2018)
Abstract: Factor VIII (FVIII)–neutralizing antibodies (inhibitors) are a serious complication in hemophilia A (HA). The peptide FVIII2194-2213 contains an immunodominant HLA-DRA*01-DRB1*01:01 (DRB1*01:01)-restricted epitope recognized by CD4+ T-eff
Externí odkaz:
https://doaj.org/article/8cdfc0df3f83466e80e9f6064c811ebe
Autor:
Bryan R. Moser, Bruce S. Dien, Denise M. Seliskar, Arthur R. Thompson, Loren B. Iten, John L. Gallagher, Steven F. Vaughn
Publikováno v:
Biomass and Bioenergy. 59:300-305
Seashore mallow ( Kosteletzkya pentacarpos (L.) Ledebour) is a perennial halophyte producing multiple, harvestable stems per year which were examined for several bioabsorbent applications. Larger, debarked stems were milled and separated into three f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2014ea211fdfad2d47a59be6d5c5b01e
https://doi.org/10.1016/j.biombioe.2013.06.010
https://doi.org/10.1016/j.biombioe.2013.06.010
Publikováno v:
Industrial Crops and Products. 51:437-443
Biochar is the solid, carbon-rich product resulting from the pyrolysis of biomass in the absence of oxygen. We are examining biochars for several horticultural applications, including as a replacement for peat moss in soilless substrates used in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37119b445e571e257fca21327b77b12f
https://doi.org/10.1016/j.indcrop.2013.10.010
https://doi.org/10.1016/j.indcrop.2013.10.010
Autor:
Arthur R. Thompson, H. Marijke van den Berg, Maurizio Margaglione, Connie H. Miller, Samantha C. Gouw, Jorien Boekhorst, Saskia le Cessie, Johanna G. van der Bom, Jan Astermark, Waander L. van Heerde, Johannes Oldenburg, Philip G. de Groot
Publikováno v:
Blood, 119, 12, pp. 2922-34
Blood, 119, 2922-34
Blood, 119(12), 2922-2934
Blood, 119, 2922-34
Blood, 119(12), 2922-2934
This systematic review was designed to provide more precise effect estimates of inhibitor development for the various types of F8 gene mutations in patients with severe hemophilia A. The primary outcome was inhibitor development and the secondary out
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89e2999cf3ffd98ae11bf952e71a70de
https://doi.org/10.1182/blood-2011-09-379453
https://doi.org/10.1182/blood-2011-09-379453
Publikováno v:
Blood. 114:1423-1428
The development of neutralizing antibodies (inhibitors) after factor VIII (FVIII) infusions is a serious complication that affects approximately one-quarter of hemophilia A patients who have access to replacement therapy. To investigate the different
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f1d8b7205f0f43979169435dbb11bdf
https://doi.org/10.1182/blood-2009-01-200725
https://doi.org/10.1182/blood-2009-01-200725
Autor:
V. Tsourea, Kathleen P. Pratt, Arthur R. Thompson, N. Sirocova, S. M. Nakaya, N. Barbacar, M. Vicol
Publikováno v:
Haemophilia. 15:942-951
Haemophilia A (HA) is a bleeding disorder caused by mutations within the X-linked F8 gene. A series of 42 unrelated Moldovan patients with HA had their disease-causative mutation determined to provide clinically valuable genotyping information for a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47f623b79f2cfb032f139791c117885e
https://doi.org/10.1111/j.1365-2516.2009.02021.x
https://doi.org/10.1111/j.1365-2516.2009.02021.x
Autor:
Arthur R. Thompson, Kathleen P. Pratt
Publikováno v:
Clinical Reviews in Allergy & Immunology. 37:80-95
Adequate hemostasis is achieved for many hemophilia A patients by infusion of plasma-derived or recombinant factor VIII (FVIII), but unfortunately, a significant subset of patients develop an immune response in which anti-FVIII antibodies, referred t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc744e09884aa6b4baf0dc5af796e028
https://doi.org/10.1007/s12016-009-8120-7
https://doi.org/10.1007/s12016-009-8120-7
Publikováno v:
Journal of Thrombosis and Haemostasis. 5:2399-2407
Summary. Background: Antibodies that neutralize factor (F) VIII activity, clinically referred to as ‘inhibitors’, complicate the treatment of hemophilia A patients; current tolerance and bypass strategies are extremely costly and sometimes ineffe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e73918eaaf4ec01140bb784db6cbde1
https://doi.org/10.1111/j.1538-7836.2007.02762.x
https://doi.org/10.1111/j.1538-7836.2007.02762.x
Publikováno v:
Haemophilia. 13:317-322
Inhibitors of FVIII are usually IgG polyclonal antibodies that develop as alloimmune responses in patients with congenital haemophilia A or as autoimmune responses resulting in acquired haemophilia. Their recognition can be difficult, especially when
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd8620b59475a8f3e9fc50e4a888e701
https://doi.org/10.1111/j.1365-2516.2007.01450.x
https://doi.org/10.1111/j.1365-2516.2007.01450.x